• 대한방사선치료학회지
• /
• 제34권
• /
• pp.83-92
• /
• 2022

목 적: 양측 유방암 방사선치료 시 토모테라피와 Halcyon 선형가속기을 이용한 치료계획을 비교하여 Halcyon 치료 계획의 유용성을 평가. 대상 및 방법: 양측 유방암 환자 10명을 대상으로 Helical Mode를 사용하여 조사면 고정 너비(Field Width, FW) 5.0-cm, 피치(Pitch) 0.287, 변조 지수(Modulation Factor) 2.4 조건의 토모테라피(Helical Tomotherapy, Accuray, USA)와 6Arc 및 8Arc의 Halcyon(Varian Medical System, Palo Alto, CA, Version 3.0 USA)을 이용한 용적변조회전치료(Volumetric Modulated Arc Therapy, VMAT)치료계획을 수립하였다. 총 처방 선량 42.4Gy/16회로 치료계획용적(Planning Target Volume, PTV)의 V _40.3Gy이 90% 이상이 되도록 하였다. 종양 및 정상 장기의 선량을 비교하여 치료 계획의 질을 평가하였고 Total MU와 Beam On Time을 비교하여 효율성을 평가하였다. 결 과: 대상 환자들의 3개 치료계획 (Tomotherapy, Halcyon 6Arc VMAT, Halcyon 8Arc VMAT)의 평가 항목 평균 값은 PTV의 H.I (Homogeneity Index)는 각각 1.07, 1.10, 1.11, PTV의 C.I (Conformity Index)는 각각 1.21, 1.16, 1.17 이었다. 정상 장기의 선량 평가 항목 평균 값은 BOTH LUNG의 V _5Gy는 각각 36.3%, 31.2%, 29.7% 이며, V _15Gy는 각각 18.6%, 15.5%, 14.6% 이었다. HEART의 평균 선량(Gy)은 각각 4.17, 2.69, 2.51 이었다. Total MU의 평균 값은 각각 7498.6, 2494.2, 2471.5 이며 Beam On Time (sec)의 평균 값은 각각 462.5, 195.4, 198 로 토모테라피와 비교하여 Halcyon VMAT 치료계획이 Beam On Time과 Total MU가 감소하였다. 결 론: Halcyon VMAT은 토모테라피와 비교하였을 때 유사한 치료 계획의 질을 보여주며 정상 장기의 더 높은 보호 효과를 나타내었다. 또한 Beam On Time과 Total MU의 감소로 방사선치료의 효율성이 증가하였다.

• Radiation Oncology Journal
• /
• 제38권1호
• /
• pp.60-67
• /
• 2020

Purpose: We performed three-dimensional (3D) dose reconstruction-based pretreatment verification to evaluate gamma analysis acceptance criteria in volumetric modulated arc therapy (VMAT) for prostate cancer. Materials and Methods: Pretreatment verification for 28 VMAT plans for prostate cancer was performed using the COMPASS system with a dolphin detector. The 3D reconstructed dose distribution of the treatment planning system calculation (TC) was compared with that of COMPASS independent calculation (CC) and COMPASS reconstruction from the dolphin detector measurement (CR). Gamma results (gamma failure rate and average gamma value [GFR and γAvg]) and dose-volume histogram (DVH) deviations, 98%, 2% and mean dose-volume difference (DD_98%, DD_2% and DD_mean), were evaluated. Gamma analyses were performed with two acceptance criteria, 2%/2 mm and 3%/3 mm. Results: The GFR in 2%/2 mm criteria were less than 8%, and those in 3%/3 mm criteria were less than 1% for all structures in comparisons between TC, CC, and CR. In the comparison between TC and CR, GFR and γAvg in 2%/2 mm criteria were significantly higher than those in 3%/3 mm criteria. The DVH deviations were within 2%, except for DD_mean (%) for rectum and bladder. Conclusions: The 3%/3 mm criteria were not strict enough to identify any discrepancies between planned and measured doses, and DVH deviations were less than 2% in most parameters. Therefore, gamma criteria of 2%/2 mm and DVH related parameters could be a useful tool for pretreatment verification for VMAT in prostate cancer.

• Radiation Oncology Journal
• /
• 제34권2호
• /
• pp.145-155
• /
• 2016

Purpose: Radiation therapy targeting axilla and groin lymph nodes improves regional disease control in locally advanced and high-risk skin cancers. However, trials generally used conventional two-dimensional radiotherapy (2D-RT), contributing towards relatively high rates of side effects from treatment. The goal of this study is to determine if three-dimensional conformal radiation therapy (3D-CRT), intensity-modulated radiation therapy (IMRT), or volumetric-modulated arc therapy (VMAT) may improve radiation delivery to the target while avoiding organs at risk in the clinical context of skin cancer regional nodal irradiation. Materials and Methods: Twenty patients with locally advanced/high-risk skin cancers underwent computed tomography simulation. The relevant axilla or groin planning target volumes and organs at risk were delineated using standard definitions. Paired t-tests were used to compare the mean values of several dose-volumetric parameters for each of the 4 techniques. Results: In the axilla, the largest improvement for 3D-CRT compared to 2D-RT was for homogeneity index (13.9 vs. 54.3), at the expense of higher lung $V_{20}$ (28.0% vs. 12.6%). In the groin, the largest improvements for 3D-CRT compared to 2D-RT were for anorectum $D_{max}$ (13.6 vs. 38.9 Gy), bowel $D_{200cc}$ (7.3 vs. 23.1 Gy), femur $D_{50}$ (34.6 vs. 57.2 Gy), and genitalia $D_{max}$ (37.6 vs. 51.1 Gy). IMRT had further improvements compared to 3D-CRT for humerus $D_{mean}$ (16.9 vs. 22.4 Gy), brachial plexus $D_5$ (57.4 vs. 61.3 Gy), bladder $D_5$ (26.8 vs. 36.5 Gy), and femur $D_{50}$ (18.7 vs. 34.6 Gy). Fewer differences were observed between IMRT and VMAT. Conclusion: Compared to 2D-RT and 3D-CRT, IMRT and VMAT had dosimetric advantages in the treatment of nodal regions of skin cancer patients.

• Asian Pacific Journal of Cancer Prevention
• /
• 제16권12호
• /
• pp.5019-5024
• /
• 2015

Background: The purpose of this study was to assess the dosimetric and clinical feasibility of volumetric modulated arc based hypofractionated stereotactic radiotherapy (RapidArc) treatment for large acoustic schwannoma (AS >10cc). Materials and Methods: Ten AS patients were immobilized using BrainLab mask. They were subject to multimodality imaging (magnetic resonance and computed tomography) to contour target and organs at risk (brainstem and cochlea). Volumetric modulated arc therapy (VMAT) based stereotactic plans were optimized in Eclipse (V11) treatment planning system (TPS) using progressive resolution optimizer-III and final dose calculations were performed using analytical anisotropic algorithm with 1.5 mm grid resolution. All AS presented in this study were treated with VMAT based HSRT to a total dose of 25Gy in 5 fractions (5fractions/week). VMAT plan contains 2-4 non-coplanar arcs. Treatment planning was performed to achieve at least 99% of PTV volume (D99) receives 100% of prescription dose (25Gy), while dose to OAR's were kept below the tolerance limits. Dose-volume histograms (DVH) were analyzed to assess plan quality. Treatments were delivered using upgraded 6 MV un-flattened photon beam (FFF) from Clinac-iX machine. Extensive pretreatment quality assurance measurements were carried out to report on quality of delivery. Point dosimetry was performed using three different detectors, which includes CC13 ion-chamber, Exradin A14 ion-chamber and Exradin W1 plastic scintillator detector (PSD) which have measuring volume of $0.13cm^3$, $0.009cm^3$ and $0.002cm^3$ respectively. Results: Average PTV volume of AS was 11.3cc (${\pm}4.8$), and located in eloquent areas. VMAT plans provided complete PTV coverage with average conformity index of 1.06 (${\pm}0.05$). OAR's dose were kept below tolerance limit recommend by American Association of Physicist in Medicine task group-101(brainstem $V_{0.5cc}$ < 23Gy, cochlea maximum < 25Gy and Optic pathway <25Gy). PSD resulted in superior dosimetric accuracy compared with other two detectors (p=0.021 for PSD.

• 한국방사선학회논문지
• /
• 제9권7호
• /
• pp.449-457
• /
• 2015

전립선암의 방사선치료에서 토모테라피와 용적변조회전치료(volumetric modulated arc therapy, VMAT)의 치료계획에 따른 유용성 평가를 위해 흡수선량, 선량체적곡선(dose volume histogram, DVH), 치료효율성, MapCHECK2를 이용한 선량 검증 정확도 결과를 각각 비교 분석하였다. 대상으로는 2014년 7월부터 12월까지 H 대학병원 방사선종양학과에서 토모테라피 치료를 받은 전립선암 환자 중 12명을 무작위로 선택하였다. 흡수선량과 DVH를 분석한 결과 종양조직과 방광에서 두 방사선 치료계획이 근소한 차이를 나타냈지만 처방선량의 오차범위인 -5%에서+3%안에 포함됐고 정상조직 부작용 확률 권고치인 견딤선량 범위를 넘지 않았다. 치료시간은 2.5배 짧고 MU(monitor unit)도 10.3배 작아 VMAT가 치료효율성이 높았다. 선량정확도는 모두 95% 이상의 통과기준에 포함 되었으며 VMAT가 2.3% 더 높게 나타났다. 토모테라피와 VMAT 모두 종양조직에 적합한 선량이 흡수되었으며 정상조직의 견딤선량 범위를 넘지 않아 선량분포특성에서 큰 차이는 없었다. 하지만 치료시간이 짧고, total MU가 낮아 치료효율성이 좋고 선량 검증의 정확도 또한 우수한 VMAT를 선택하는 것이 치료에 더 유용할 것으로 사료된다.

• 한국의학물리학회지:의학물리
• /
• 제24권4호
• /
• pp.295-302
• /
• 2013

간암 환자에 대한 세기조절방사선치료(IMRT, intensity modulated radiotherapy) 및 세기조절회전방사선치료(VMAT, volumetric arc therapy)와 나선식토모치료(TOMO, Helical Tomotherapy)에서 2차 암의 원인이 될 수 있는 산란 및 누출선량률을 평가하였다. 5명의 간암 환자에 대해 IMRT와 VMAT, TOMO 치료계획을 실시하여 등중심(iso-center)으로부터 20, 40, 60, 80 cm 위치에서 유리선량계(RPLGD, radiophotoluminescence glass dosimeter)를 이용하여 선량을 측정하였다. 계획표적체적(Planning Target Volume, PTV)에 조사된 단위 선량(Gy)당 측정된 산란 및 누출선량은 IMRT의 경우, 최소 0.01에서 최대 3.13 Gy로 측정 되었고 VMAT에 대해서는 최소 0.03에서 최대 2.35 Gy까지, TOMO에 대해서는 최소 0.04에서 최대 1.30 Gy 까지 측정 되었다. 각 치료법에 대한 평균장기등가선량은 세기조절방사선치료에 대해 세기조절회전방사선 치료와 나선식단층토모치료가 각각 갑상선에서 75%와 51%, 대장에서 75%와 41%, 직장에서 72%와 48%, 전립선에서 76%와 50%로 나왔다. 본 측정을 통하여 산란 및 누출선량은 치료 중심으로부터의 거리에 따라 감소함을 보았으며 TOMO 치료의 경우, 환자치료를 위해 사용하는 모니터단위(MU, monitor unit)가 타 치료법에 비해 상대적으로 큼에도 불구하고 산란 및 누출선량은 크지 않는 것으로 평가되었다.

• 한국의학물리학회지:의학물리
• /
• 제29권4호
• /
• pp.157-163
• /
• 2018

Plans converted using dose-volume-histogram-based plan conversion (DPC) were evaluated by comparing them to the original plans. Changes in the dose volumetric (DV) parameters of five volumetric modulated arc therapy (VMAT) plans for head and neck (HN) cancer and five VMAT plans for prostate cancer were analyzed. For the HN plans, the homogeneity indices (HIs) of the three planning target volumes (PTV) increased by 0.03, 0.02, and 0.03, respectively, after DPC. The maximum doses to the PTVs increased by 1.20, 1.87, and 0.92 Gy, respectively, after DPC. The maximum doses to the optic chiasm, optic nerves, spinal cord, brain stem, lenses, and parotid glands increased after DPC by approximately 4.39, 3.62, 7.55, 7.96, 1.77, and 6.40 Gy, respectively. For the prostate plans after DPC, the HIs for the primary and boost PTVs increased by 0.05 and 0.03, respectively, and the maximum doses to each PTV increased by 1.84 and 0.19 Gy, respectively. After DPC, the mean doses to the rectum and femoral heads increased by approximately 6.19 and 2.79 Gy, respectively, and those to the bladder decreased by 0.20 Gy when summing the primary and boost plans. Because clinically unacceptable changes were sometimes observed after DPC, plans converted by DPC should be carefully reviewed before actual patient treatment.

• 한국의학물리학회지:의학물리
• /
• 제32권4호
• /
• pp.107-115
• /
• 2021

Purpose: The purpose of this study was to compare the clinical quality assurance results of portal dosimetry using an electronic portal imaging device, a method that is extensively used for patient-specific quality assurance, and the newly released Mobius3D for intensity-modulated radiotherapy (IMRT) and volumetric modulated arc therapy (VMAT). Methods: This retrospective study includes data from 122 patients who underwent IMRT and VMAT on the Novalis Tx and VitalBeam linear accelerators between April and June 2020. We used a paired t-test to compare portal dosimetry using an electronic portal imaging device and the average gamma passing rates of MobiusFX using log files regenerated after patient treatment. Results: The average gamma passing rates of portal dosimetry (3%/3 mm) and MobiusFX (5%/3 mm) were 99.43%±1.02% and 99.32%±1.87% in VitalBeam and 97.53%±3.34% and 96.45%±13.94% in Novalis Tx, respectively. Comparison of the gamma passing rate results of portal dosimetry (3%/3 mm) and MobiusFX (5%/3 mm as per the manufacturer's manual) does not show any statistically significant difference. Conclusions: Log file-based patient-specific quality assurance, including independent dose calculation, can be appropriately used in clinical practice as a second-check dosimetry, and it is considered comparable with primary quality assurance such as portal dosimetry.

• 대한방사선치료학회지
• /
• 제33권
• /
• pp.89-97
• /
• 2021

목 적: 본 연구에서는 자궁경부암 방사선치료 시 전산화치료계획에 없던 직장 내 가스 용적 변화에 따른 선량변화를 비교 평가하고자 한다. 대상 및 방법: 인체모형 팬텀(Anderson Research Laboratories Inc, RANDO^TM phantom, USA)의 전산화 단층촬영 영상에 전산화치료계획시스템(Eclipse^TM Treatment Planning System, Varian, Palo Alto, version 15.6, USA)으로 9개의 필드를 이용한 정적 세기조절방사선치료계획(Static Intensity Modulated Radiation Therapy, S-IMRT)과 Full arc로 두 방향의 체적변조회전방사선치료계획(Volumetric Modulated Arc Therapy, VMAT)을 수립하였다. 임의의 가스 변수는 0.5 cm 단위로 2.0 cm까지 변화를 주어 계획표적체적(Planning Target Volume, PTV)에 포함될 수 있도록 하였다. 표적에 대한 처방선량지수(Conformity Index, CI), 선량균질지수(Homogeneity Index, HI), PTV D_max를 구하였고, 손상위험장기(Organ At Risk, OAR)에 대한 최소선량(Minimum Dose, D_min)과 평균선량((Mean Dose, D_mean), 최대선량(Maximum Dose, D_max)을 계산하여 비교하였다. T-검정을 실시하여 p-value를 구했으며 유의수준은 0.05로 설정하였다. 결 과: S-IMRT와 VMAT의 HI 결정계수(R²)는 0.9423, 0.8223으로 상관관계가 비교적 명확하였고, PTV D_max 결과 임의의 가스 용적이 커질수록 최대 2.8%까지 증가하는 것으로 나타났다. OAR의 경우 두 전산화치료계획 모두 방광에서 유의한 차이가 없었고, 직장의 경우 +1.0 cm 이상의 가스 용적에서 두 전산화치료계획 모두 D_mean 700 cGy 이상의 유의한 선량 차이가 나타났다. 방광의 D_mean을 제외한 모든 값에서 p-value 0.05 이하로 통계적인 유의한 차이를 확인하였다. 결 론: 기준 전산화치료계획에 없던 가스 발생 시 가스 용적 크기가 커질수록 PTV의 선량 변화와 직장에 전달되는 선량이 증가하였다. 방사선치료 진행 시 직장 가스의 용적이 클 경우 발생 할 수 있는 선량 전달 오류를 최소화하기 위한 노력이 반드시 필요한 것으로 판단되었다. 향후 가스 용적의 다양한 크기와 위치를 변수로 설정하여 추가적인 연구가 진행되어진다면 유익한 평가가 이루어 질 수 있을 것으로 사료된다.

• 한국의학물리학회지:의학물리
• /
• 제33권4호
• /
• pp.121-128
• /
• 2022

Purpose: This study evaluated the quality of plans based on magnetic resonance-guided radiotherapy (MRgRT) tri-Co-60, linac, and conventional linac-based volumetric modulated arc therapy (linac-VMAT) for prostate cancer. Methods: Twenty patients suffering from prostate cancer with intermediate risk who were treated by MAT were selected. Additional treatment plans (primary and boost plans) were generated based on MRgRT-tri-Co-60 and MRgRT-linac. The planning target volume (PTV) of MRgRT-based plans was created by adding a 3 mm margin from the clinical target volume (CTV) due to high soft-tissue contrast and real-time motion imaging. On the other hand, the PTV of conventional linac was generated based on a 1 cm margin from CTV. The targets of primary and boost plans were prostate plus seminal vesicle and prostate only, respectively. All plans were normalized to cover 95% of the target volume by 100% of the prescribed dose. Dosimetric characteristics were evaluated for each of the primary, boost, and sum plans. Results: For target coverage and conformity, the three plans showed similar results. In the sum plans, the average value of V_65Gy of the rectum of MRgRT-linac (2.62%±2.21%) was smaller than those of MRgRT tri-Co-60 (9.04%±3.01%) and linac-VMAT (9.73%±7.14%) (P<0.001). In the case of bladder, the average value of V_65Gy of MRgRT-linac was also smaller. Conclusions: In terms of organs at risk sparing, MRgRT-linac shows the best value while maintaining comparable target coverage among the three plans.